Latest Biotech News

Researchers reported a CRISPR-based method that reprograms mitochondrial function after myocardial injury, proposing a direct genetic route to restore cardiac energy metabolism. The study details...

Baylor University researchers engineered Listeria monocytogenes to act as a vector that invades colorectal tumors and delivers cytotoxic proteins directly into cancer cells. The study shows the...

Bristol Myers Squibb announced that mezigdomide, an oral protein-degrading CELMoD, met a primary endpoint in a late-stage trial for relapsed or refractory multiple myeloma, showing a statistically...

Xenon Pharmaceuticals reported a positive Phase 3 X-Tole2 study for azetukalner, a KV7 potassium channel opener, with large placebo-adjusted reductions in focal-onset seizure frequency and a...

Ipsen announced a voluntary withdrawal of tazemetostat (Tazverik) after an independent data monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial in...

Novo Nordisk and Hims & Hers reached an agreement under which Hims will offer Novo’s GLP‑1 medicines at standard telehealth prices and limit promotion of compounded alternatives. Novo agreed to...

Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to broaden its pathology portfolio with Biocare’s immunohistochemistry, in situ hybridization and FISH assays and a...

Sartorius launched a rationally designed CHO host cell line that the company reported delivers up to two‑fold higher expression titers and up to three‑fold productivity gains across multiple...

Lonza and Genetix Biotherapeutics renewed and expanded their commercial manufacturing agreement to support growing demand for ZYNTEGLO, the FDA‑approved gene therapy for transfusion‑dependent...

The World Health Organization said it will issue recommendations supporting a new class of near‑point‑of‑care molecular TB tests, adoption of tongue‑swab sampling, and pooled sputum testing to...

Roche announced that its oral selective estrogen receptor degrader (SERD) giredestrant failed to meet the primary endpoint in a Phase 3 first‑line breast‑cancer study. The miss contrasts with...

Xenon Pharmaceuticals reported Phase 3 results showing azetukalner produced a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose, exceeding prior expectations and...

Ipsen said it will withdraw the EZH2 inhibitor Tazverik from the market after independent monitors identified cases of secondary hematologic malignancies in a confirmatory trial for follicular...

Novo Nordisk and Hims & Hers struck a deal to list Novo’s GLP‑1 medicines on Hims’ telehealth platform at the same prices available through other telehealth providers. Under the agreement Hims...

AbbVie released early data from its high‑stake amylin program showing near‑10% weight loss at 12 weeks in certain patients, signalling initial efficacy for the company’s $350 million investment in...

Lonza agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds in a transaction valued at CHF 2.3 billion (~$3 billion), retaining a 40% stake and planning to reinvest...

Lonza and Genetix extended their commercial manufacturing agreement to expand production of ZYNTEGLO™ at Lonza’s Houston cell and gene therapy site. The renewed deal secures additional capacity to...

Stocks of gene‑therapy developers swung sharply after reports that Vinayak (Vinay) Prasad will step down as FDA CBER director, a change that followed high‑profile agency demands for additional...

Cenevo introduced two agentic AI tools—the AI Protocol Conversion agent and the AI Automation agent—designed to convert legacy protocols into structured, compliant digital workflows and to...

Agilent agreed to acquire Biocare Medical for $950 million in cash, adding immunohistochemistry (IHC), in‑situ hybridization (ISH), FISH assays and a library of over 300 specialized antibodies to...